EHA 2019 | BET Inhibitor pelabresib (CPI-0610) and ruxolitinib for myelofibrosis

Name: BET Inhibitor pelabresib (CPI-0610) and ruxolitinib for myelofibrosis
Uploaded: 2019-06-15T00:00:00.000Z
Duration: 1 min 27 s
Description: Here, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, presents updates on the use of the BET Inhibitor pelabresib (CPI-0610) in combination with ruxolitinib for myelofibrosis. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Srdan Verstovsek • 15 Jun 2019

EHA 2019

Myelofibrosis Pelabresib Ruxolitinib

Here, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, presents updates on the use of the BET Inhibitor pelabresib (CPI-0610) in combination with ruxolitinib for myelofibrosis. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.